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Background: Recent progress in genome data collection and analysis technologies has led to a surge of direct-to-consumer
(DTC) genetic testing services. Owing to the clinical value and sensitivity of genomic data, as well as uncertainty and hearsay
surrounding business practices of DTC genetic testing service providers, DTC genetic testing has faced significant criticism by
researchers and practitioners. Research in this area has centered on ethical and legal implications of providing genetic tests directly
to consumers, but we still lack a more profound understanding of how businesses in the DTC genetic testing markets work and
provide value to different stakeholders.
Objective: The aim of this study was to address the lack of knowledge concerning business models of DTC genetic testing
services by systematically identifying the salient properties of various DTC genetic testing service business models as well as
discerning dominant business models in the market.
Methods: We employed a 3-phased research approach. In phase 1, we set up a database of 277 DTC genetic testing services.
In phase 2, we drew on these data as well as conceptual models of DTC genetic testing services and iteratively developed a
taxonomy of DTC genetic testing service business models. In phase 3, we used a 2-stage clustering method to cluster the 277
services that we identified during phase 1 and derived 6 dominant archetypes of DTC genetic testing service business models.
Results: The contributions of this research are 2-fold. First, we provided a first of its kind, systematically developed taxonomy
of DTC genetic testing service business models consisting of 15 dimensions in 4 categories. Each dimension comprises 2 to 5
characteristics and captures relevant aspects of DTC genetic testing service business models. Second, we derived 6 archetypes
of DTC genetic testing service business models named as follows: (1) low-cost DTC genomics for enthusiasts, (2) high-privacy
DTC genomics for enthusiasts, (3) specific information tests, (4) simple health tests, (5) basic low-value DTC genomics, and (6)
comprehensive tests and low data processing.
Conclusions: Our analysis paints a much more complex business landscape in the DTC genetic testing market than previously
anticipated. This calls for further research on business models and their effects that underlie DTC genetic testing services and
invites specific regulatory interventions to protect consumers and level the playing field.
(J Med Internet Res 2020;22(1):e14890)  doi: 10.2196/14890
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When 23andMe opened its Web store to the public in 2007, it
was among the first in the second wave of the so-called
direct-to-consumer (DTC) genetic testing services that
publicized the idea of personal genomics [1]. The surge of DTC
genetic testing services such as 23andMe, Ancestry.com, or
FamilyTreeDNA, to name a few, during the last decade is
thereby mainly driven by the rapidly declining costs for
collecting and analyzing genome data [2] and the public’s
growing interest in genomics [3]. Overall, estimates suggest
that the global DTC genetic testing market will be worth
approximately US $610 million by 2026 [4].
DTC genetic testing refers to genetic tests targeted toward
consumers that do not require the involvement of a medical
professional in mediating the service and interpreting it [5].
Typical tests offered by DTC genetic testing services include
ancestry tests, nonmedical lifestyle tests (eg, traits, fitness,
nutrition), and medical tests (eg, carrier status, genetic health)
[3]. Compared with conventional medical testing, DTC genetic
tests are, however, initiated by consumers, not their physicians,
and sold directly to consumers over the internet [6].
Consequently, consumers are responsible for controlling and
managing their genetic information on the Web, as well as
choosing an interpreter for their genetic information or
interpreting it themselves [6]. Despite the ongoing proliferation
of genetic testing and the public’s rising interest therein, DTC
genetic testing has been a source of controversy ever since the
inauguration of the first services offering such tests [5]. This
especially pertains to business practices underlying DTC genetic
testing services, as it is often believed that such services resell
access to their consumers’ genetic data to increase revenue and
to compensate for selling budget-priced tests. 23andMe, for
example, uses its DTC front end to build a health information
database and sells access to this database to clinical research
and biopharmaceutical companies [7]. Concerns about the
impact and business practices of DTC genetic testing services
climaxed in several professional associations recommending to
consumers to refrain from using DTC genetic testing services
at all [5] and the US Food and Drug Administration (FDA)
sending out cease and desist letters to several DTC genetic
testing services in 2013 [6].
To realize the full potential of a disruptive technology such as
genetic testing, it needs to be met by innovative business models
[8]. Toward this end, DTC genetic testing can be regarded as a
class of business models that can serve to make genetic testing
more affordable and accessible. In light of the glaring
contradiction between the ongoing proliferation of DTC genetic
testing services, on the one hand, and the spreading skepticism
toward their business practices on the other hand [9], however,
there still seems to be little consensus among providers of such
services, policy makers, professionals, and the general public
on what actually constitutes suitable business models for DTC
genetic testing. Several DTC genetic testing services, for
example, recently started to shift their business models toward
greater involvement of medical professionals and test approvals
by regulatory bodies [6]. This resulted in the FDA-granting
approvals for certain DTC genetic tests [6], which is likely to
provide additional impetus to this market. Thus far, research
provides little guidance for assessing or developing business
models in the context of DTC genetic testing. Owing to the
clinical value and sensitivity of genome data, past research on
DTC genetic testing has primarily focused on ethical and legal
issues surrounding genetic tests offered directly to consumers
[10], including impact and clinical utility of DTC genetic tests
[11], as well as studies of awareness and perceptions of DTC
genetics and its risks [12-14]. Most of our knowledge about
business models of DTC genetic testing services today stems
from newspaper articles [15], blogposts discussing specific DTC
genetic testing services [7], or company reports [16]. To the
best of our knowledge, so far only a single white paper explicitly
investigates business models underlying DTC genetic testing
services (cf, the Business Models in Genomics section), and
there are no published academic articles on this topic. A first
step toward closing this knowledge gap pertains to scrutinizing
the status quo and understanding what characterizes business
models in the DTC genetic testing context today as well as what,
if any, dominant business models have emerged in this market.
We therefore ask the following research questions:
• RQ1: What are salient properties of DTC genetic testing
service business models?
• RQ2: What dominant business models of DTC genetic
testing services have emerged?
To answer these research questions, we develop a taxonomy of
DTC genetic testing service business models (RQ1) and
subsequently draw on this taxonomy to derive archetypes of
DTC genetic testing service business models (RQ2). In doing
so, we provide a systematic classification of DTC genetic testing
service business models and expose their essential
characteristics. We posit that the knowledge encapsulated in
the taxonomy and dominant archetypes makes fruitful
contributions to research on the role and impact of building
innovative (internet-based) business models in health care. It
can aid policy makers to better understand how DTC genetic
testing services operate and design policies and regulations to
protect consumers and enable fair competition when possible
while realizing their full potential. Moreover, it should also help
addressing health professionals’ concerns regarding the impact
of these services and increase consumers’ awareness to make
more informed decisions about using such services. Finally, for
nascent businesses in the DTC genetic testing industry, our
findings can serve as a blueprint of the emerging competitive
landscape and as a roadmap to advance their business models.
Business Models in Genomics
Despite the term business model being commonly used in
management and strategy, little consensus prevails over what
constitutes a business model [17]. Extant literature has proposed
an abundance of definitions for business models [8,18,19].
Drawing on Shafer et al [17], who synthesized extant
conceptualizations of business models within scientific literature,
we understand a business model as “a representation of a firm’s
underlying core logic and strategic choices for creating and
capturing value within a value network.” Consequently, business
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models comprise 4 major categories of components: (1) strategic
choices (eg, customers, target markets, value propositions,
revenues and pricing, competitors), (2) value creation (eg, key
resources, assets, processes), (3) value network (eg, information
and product flows between an organization, its suppliers, and
customers), and (4) capturing value (eg, profit-making
mechanisms).
As pointed out earlier, disruptive technologies like genetic
testing must be met by innovative business models to realize
their full potential [8]. However, the health care sector is
knowingly slow in adopting disruptive technologies, especially
the innovative business models that these technologies afford
[8,20]. Looking at genetic testing, we see that this nascent but
arguably increasingly important aspect of modern health care
is no exception to this phenomenon. Toward this end, scientific
literature on the business aspects of DTC genetic testing
services, especially their underlying business models, remains
scarce [21]. The stream of research that is closest to this topic
relates to socioeconomic research on DTC genetic testing [1].
Research in this stream is concerned with the marketing
strategies of DTC genetic testing services and their impact on
consumers [22,23], as well as economic implications of
consumers freely sharing their genome data [24-26]. Extant
literature has also covered the history [27] and size [28] of the
global DTC genetic testing market. Our review of the related
literature resulted, however, in only 1 white paper by Vanhala
and Reijonsaari [29] that explicitly investigates business models
in the context of DTC genetic testing. They define a business
model as connecting consumers’ needs with the solution offered
by a service. Accordingly, any DTC genetic testing service
business model comprises value propositions, distribution
channels, revenue logic, customer segments, and key resources
(eg, genome data). On the basis of these 5 business model
aspects, Vanhala and Reijonsaari [29] further derive 5 categories
of DTC genetic testing service business models: (1)
comprehensive genomic tests for consumers and as genome
data bank material (eg, 23andMe), (2) genomics as part of
individual health planning (eg, MD Revolution), (3) genomic
services based on comprehensive genetic testing (eg,
Genetrainer), (4) medical precision tests for consumers (eg,
Myriad Genetics), and (5) restricted trait tests (eg,
Genecodebook Oy) [29]. Although this categorization certainly
is a valuable step toward shedding light onto DTC genetic
testing service business models, the authors provide little
information on the employed methodology and base their
analysis on assessing only a limited number of DTC genetic
testing services. Adding to this, the study was published in 2013
and thus does not account for recent changes in the landscape
of DTC genetic testing service business models.
Methods
Overview
To answer our research questions, we adopted the 3-phased
approach of Remane et al [30]. A detailed description of each
phase is given later, and Table 1 provides a brief summary of
the individual phases.
Table 1. Overview of the research approach.
Phase 3: Cluster analysisPhase 2: Taxonomy developmentPhase 1: Database setupPhases
Inputs ••• DTC genetic testing service business
model taxonomy
DTCa genomics literature (deductive
iterations)
Desk research
• Web-based genetic testing service
repositories [31-33] • List of DTC genetic testing services
(inductive iterations)
Steps ••• Identify suitable numbers of clusters
(Ward’s method)
Define a meta-characteristicCompile a list of DTC genetic testing
services • Develop taxonomy iteratively until all
ending conditions are met •• Run iterative partitioning algorithm
with the identified numbers of suitable
clusters
Filter services not available anymore
• Collect information about services
from multiple sources (eg, websites,
blogs, research, or news articles) • Select the most fit cluster solution
• Analyze cluster solution and derive
archetypes
Outcomes ••• 6 archetypes of DTC genetic testing
service business models
Taxonomy of DTC genetic testing
services' business models with 41
characteristics in 15 dimensions
List of 277 DTC genetic testing ser-
vices
aDTC: direct-to-consumer.
Phase 1: Database Setup
In phase 1, a database of DTC genetic testing services was set
up. It served as a basis for taxonomy development and cluster
analysis in phases 2 and 3, respectively. As we are solely
interested in DTC genetic testing services that have a Web
presence, the internet provided a good starting point to collect
information about these kinds of services. We therefore
conducted a desk search using the internet to set up our database.
Our search led to the identification of 3 central resources that
list a large body of genomic service providers (not limited to
DTC genetic testing services). First, Phillips [31] has compiled
a comprehensive list of 301 DTC genetic testing services, which
is available on her website. Second, DNA Testing Choice [32],
a UK-based news and reviews service of genetic tests, offers
rankings for a variety of DTC genetic tests. As some DTC
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genetic testing services may offer more than one test, they may
also appear in multiple rankings on DNA Testing Choice.
Finally, the International Society of Genetic Genealogy [33]
also provides a list of DTC genetic testing services. Overall, all
3 sources together listed 428 genetic testing services. For each
service, we noted its name, website, a brief service description,
and relevant sources (ie, websites that reference the respective
service). As the focus of this study is on DTC genetic testing
services, we screened all entries for DTC genetic tests before
the taxonomy development process. This led to the exclusion
of 171 services that were either not available anymore or did
not fit our definition of DTC genetic testing services (eg,
services that offered genetic testing of animals). We further
identified 20 additional DTC genetic testing services while
collecting information about services already included. In total,
our final database contains 277 DTC genetic testing services.
A complete list of services included in and excluded from our
database can be found in Multimedia Appendix 1.
Phase 2: Taxonomy Development
The second phase focused on the development of a taxonomy
of DTC genetic testing service business models (thus answering
RQ1). Taxonomies are important tools in scientific disciplines
as they provide researchers with fundamental categories to
analyze and understand complex domains [34]. We based the
development of our taxonomy on the method by Nickerson et
al [34]. It provides a systematic approach (as opposed to an ad
hoc approach) to taxonomy development that combines
inductive and deductive reasoning and has been extensively
used to systematically develop taxonomies for phenomena in
health care [35-42] and other domains [30,34,43,44]. The
method consists of 7 iterative steps and provides guidelines for
each step in the taxonomy development process. Step 1 abides
the selection of a so-called meta-characteristic. Being the most
comprehensive characteristic, the meta-characteristic serves to
avoid a situation of naïve empiricism, acting as the basis for the
choice of characteristics included in the taxonomy [34]. Each
characteristic in the taxonomy must therefore be a logical
consequence of the meta-characteristic [34]. Drawing on RQ1,
we defined our meta-characteristic as salient properties of
business models of DTC genetic testing services. As steps 3 to
7 of the taxonomy development are iterative, some
predetermined conditions that end the process must be defined
in step 2. For this research, we adopted the 5 subjective ending
conditions (ie, conciseness, robustness, comprehensiveness,
extendibility, and explanatory) and 8 objective ending conditions
(eg, characteristics in a dimension are mutually exclusive, and
there were no changes made to the taxonomy during the last
iteration) provided by Nickerson et al [34]. Next, steps 3 to 7
involve the iterative development of the taxonomy (cf,
Multimedia Appendix 2), whereby each iteration starts by
choosing either a conceptual-to-empirical (deductive) or
empirical-to-conceptual (inductive) approach in step 3 and ends
with a review of whether the ending conditions are met in step
7 [34]. If the ending conditions are not met, an additional
iteration is performed.
In total, we performed 7 iterations. An overview of the
development of dimensions for individual iterations is given in
Figure 1. The first iteration followed the conceptual-to-empirical
approach and was based on the model of Vanhala and
Reijonsaari [29]. It led to an initial taxonomy with 8 dimensions.
We classified DTC genetic testing services examined by
Vanhala and Reijonsaari [29] and the top 10 ancestry, paternity,
and health test service providers according to DNA Testing
Choice [32] in the second iteration to verify the validity of our
initial taxonomy. This led to the addition of 2 new dimensions.
Figure 1. Overview of the taxonomy development iterations.
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Before the next iteration, we grouped all services based on the
tests they offered. Similar to DNA Testing Choice’s ranking
categories, we grouped services into 1 of the 3 categories: (1)
genomics enthusiasts (eg, ancestry, genetic dating, trait testing),
(2) relationship tests (eg, paternity, maternity), and (3) health
tests. Like iteration 2, iteration 3 also followed the
empirical-to-conceptual approach. After the analysis of the
genomics enthusiasts subset, we added 3 dimensions. At this
point, a review of dimensions and characteristics in iteration 4
(conceptual-to-empirical) resulted in the addition of 1 further
dimension. In iteration 5 (empirical-to-conceptual), we analyzed
all services offering relationship tests, which led to the addition
of 1 new dimension. The following iteration 6 again followed
the conceptual-to-empirical approach. Within this iteration, we
merged 2 dimensions and split 1 dimension into 2 distinct
dimensions. During iteration 7, the remaining subset of Health
Tests was examined, which led to no alterations to the taxonomy.
At this stage, the taxonomy fulfilled all ending conditions after
7 iterations (cf, Multimedia Appendix 3).
Phase 3: Cluster Analysis
The third phase focused on deriving archetypes of DTC genetic
testing service business models (RQ2) using the previously
created taxonomy as a baseline for cluster analysis. Cluster
analysis is a process of finding distinct groups of objects (ie,
clusters) in data [45]. The objective is to find groups (clusters)
for which the objects of 1 group are highly similar in selected
attributes, whereas they are as dissimilar as possible from objects
in the other groups [45]. An abundance of clustering methods
is available, and choosing the most suitable method can be
cumbersome and error prone in terms of what similarity or
dissimilarity measure to choose, how many clusters to generate,
or overall performance of clustering algorithms [46]. Iterative
partitioning algorithms such as k-means, for example, provide
better performance than hierarchical clustering methods, but in
turn usually require the a priori definition of how many clusters
to produce [46]. To address these problems, we adopted the
2-stage clustering approach suggested by Punj and Stewart [46].
In this process, the first stage utilizes a hierarchical method to
determine a preliminary solution, which can be used to deduce
candidate numbers of clusters that serve as starting points for
the iterative partitioning algorithm in stage 2. On the basis of
the candidate number of clusters obtained in stage 1, an iterative
partitioning algorithm arranges the included objects in their
final cluster solution in stage 2 [46]. According to Remane et
al [30], we utilized Ward’s method for stage 1 and the k-means
algorithm for stage 2.
Ward’s method is an agglomerative clustering procedure. It
starts by combining the 2 objects closest to each other into 1
cluster and repeats this process until all objects belong to the
same cluster [47]. During each iteration, the similarity between
2 clusters is calculated by the number of identical characteristics.
As our taxonomy holds only binary data (ie, a characteristic is
either applicable or not), the squared Euclidean distance, which
places progressively greater weight on objects that are further
apart from each other, is a suitable similarity measure [30]. The
dendrogram produced by Ward’s method indicated that a 4-,
5-, or 6-cluster solution would have the most explanatory power
for our dataset. Also, by reviewing the scree plot, the elbow
rule suggested the 4-, 5-, 7-, or 9-cluster solution in this
particular order. With the preliminary cluster solutions in place,
we used the k-means method to derive our final cluster solution
in the second stage. The k-means method produces a partition
of the dataset into an a priori defined number of clusters [47].
Starting with an initial partition, objects are moved into other
clusters if they are closer to its mean vector than that of their
current cluster, usually calculated using Euclidean distance.
After each iteration, the mean vectors are updated [47]. The
procedure continues until all objects are closer to the mean
vector of their own cluster than to the mean vectors of any of
the other clusters or no significant changes are found [47]. For
the 4, 5, 6, 7, and 9 cluster solutions, the algorithm ran through
10, 17, 9, 13, and 12 iterations before achieving convergence,
respectively. However, retrieved significance values for
characteristics (ie, how relevant a certain characteristic is for
the cluster solution) indicated that the 4 and 5 cluster solutions
were of inadequate quality because they possessed too many
irrelevant characteristics (cf, Multimedia Appendix 4). We
therefore did not consider those cluster solutions any further.
The remaining cluster solutions (ie, 6, 7, and 9 clusters) were
next manually compared for their explanatory power by 2
researchers (ie, we sought to find meaningful interpretations
for all clusters in all cluster solutions). Although we were able
to find meaningful interpretations for the 7-cluster solution, it
produced entirely different clusters, which we deemed less
meaningful and providing little to no additional insight
compared with the 6-cluster solution. For the 9-cluster solution,
on the other hand, we were unable to find meaningful
interpretations for all clusters. Hence, we selected the 6-cluster
solution as the most suitable one for this study and report it
below.
Results
Direct-to-Consumer Genetic Testing Service Business
Models Taxonomy
Our final taxonomy consists of 15 dimensions. Each dimension
consists of 2 to 4 characteristics, with a total of 41
characteristics. Furthermore, the dimensions have been grouped
into 4 categories based on the previously outlined categories of
components of business models (ie, strategic choices, value
network, create value, and capture value) to provide a better
understanding of how the dimensions relate to each other. Table
2 offers an overview of the final taxonomy, whereas the results
of our coding can be found in Multimedia Appendix 5. In the
following, we describe each dimension and its characteristics
in detail.
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Table 2. Taxonomy of direct-to-consumer genetic testing services’ business models.
CharacteristicsDimension
Strategic choices
For profit; nonprofitBusiness purpose
Local; worldwideRegion of operation
Enthusiasts; specific information seekers; enthusiasts and specific information seekers; chronic health issue and
risk group
Consumer target group
Mandatory; optional; data not usedConsumer research consent
Value network
Internet only; health care professionals only; multicontact serviceDistribution channel
Home collection; lab collection; home and lab collectionSampling site
Service provider; third party; service provider and third partySampling kit provider
Never; mandatory; consumer decisionSample storage
Create value
Genotyping; sequencing; genotyping and sequencingGenome test type
No storage; isolated storage; database for service providerData storage
Consumer; service providerData ownership
No interpretation; basic interpretation; value-added interpretationData processing
Capture value
Pay-per-use; pay-per-use and subscription; no feeFee type
Consumer only; consumer and health insuranceFee payer
Yes; noReselling of genome data
Strategic Choices
The first category of components of a business model entails 4
dimensions related to strategic choices of a DTC genetic testing
service, such as target markets and customers. The business
purpose dimension answers the basic question of whether a
service provider seeks to generate profit or whether it is a
nonprofit organization that contributes to genomics research
and makes DTC genetic testing more accessible to consumers.
The region of operation dimension answers the question where
a DTC genetic testing service is offered. In our taxonomy, we
distinguish between the characteristics local (ie, tests are only
available in the country the service has been registered in) and
worldwide (ie, tests are offered all over the world with the
exception of countries that do not allow such tests by law). The
third dimension, consumer target group, divides DTC genetic
testing services into 4 target groups. Products aimed at
enthusiasts seek to spark the curiosity of the consumer for
information on their DNA such as ancestry, taste tests, lactose
intolerance, or health traits [29]. The second target group
concerns specific information seekers. Services for this target
group offer genetic tests that aim to answer a specific question
and include, for example, paternity and other relationship tests,
immigration tests, or tests for certain diseases. There are also
genetic testing services that target both enthusiasts and specific
information seekers and are summarized in the third
characteristic of this dimension. The last target group addresses
consumers dealing with chronic health issues and related risks
(eg, individuals with diabetes, individuals with high blood
pressure, or individuals with an increased risk of cancer).
Finally, the consumer research consent option dimension
indicates whether DTC genetic testing service providers ask for
consumers’ consent to use their data for research. For some
services, it is mandatory that consumers give their consent for
using their data for research to purchase the service. Other
service providers either give consumers the option to consent
into their personal genome data being used for research or do
not utilize their customers’ data for research purposes at all.
Value Network
The value network category comprises 4 dimensions that
characterize a DTC genetic testing service’s relationship to key
partners and customers, as well as how information, products,
and services flow through this network. The distribution channel
dimension describes how products and services are
communicated and offered to the consumer. Although many
DTC genetic testing service providers only offer an internet
presence for all consumer means, some service providers may
require a health care professional to be involved. However,
health care professionals mainly serve as a means for distributing
and, in some cases, carrying out sample collection and follow-up
patient counseling but are responsible neither for performing
the actual genetic testing nor for interpreting test results. The
third and most comprehensive distribution channel is described
as a multicontact service [29]. This includes internet solutions,
mobile apps, telephone consulting, stores, and home visits to
offer the product to the consumers. The sampling site dimension
summarizes where a consumer’s genome sample is collected.
Many services offer the collection of genetic material via home
collection kits that are mailed to their consumers. The sample
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is then taken by the consumers themselves (eg, buccal swab or
saliva sample) and sent back for analysis. Other services require
their consumers to visit a lab, where samples are taken by the
staff. Lab collection is usually offered either as a convenience
to the consumer or because it is legally required (eg, a paternity
test that is to be acknowledged by the court). Some services
offer home and lab collection of genome samples. Adding to
this, the sampling kit provider dimension describes whether a
service provider offers their own sample collection kit or
whether a third-party sample collection kit is used. Some
services offer both, their own sample collection kit and the
option to use a third-party kit. Finally, the sample storage
dimension indicates whether the collected sample is destroyed
(ie, never stored) or kept after the genome data have been
generated. Although for some genetic testing services it is
mandatory that genetic samples are kept (eg, for legally binding
paternity tests), others leave this decision up to their customers.
Create Value
The third category contains 4 dimensions, which describe how
DTC genetic testing services create value for customers. It thus
focuses on their products and processes. The genome test type
dimension determines what kind of method is used to generate
genome data and consists of three characteristics. A service
provider may either offer genotyping only, sequencing (whole
genome or whole exome) only, or both, genotyping and
sequencing. Next, the data storage dimension considers how
DTC genetic testing services store the genome data of their
consumers. Service providers can either not store the produced
data, store it isolated for the consumers’ access only, or store
it in a common database, which is used to improve service
quality. If the data are not stored, then they are deleted shortly
after the consumers retrieve their genome data. Some services
collect fees for the isolated storage of the data and will only
keep it as long as the consumers decide to store it. The data
ownership dimension classifies DTC genetic testing services
in terms of who owns the genome data. By purchasing a product
from a service, the consumers agree to their terms of service.
The terms of service usually state whether the collected genome
data are the property of the consumers or the service provider.
If the ownership stays with the consumers, the decision power
over the data also remains with the consumers. If a business
claims ownership of the data, then it is authorized to use the
data without restrictions to further the company’s interests.
Finally, the fourth and last dimension, data processing, describes
the degree of genome data analysis provided by a service. Some
DTC genetic testing services do not offer any interpretation but
instead deliver the raw genome data by means of genotyping
or DNA sequencing, only. If services offer interpretation of the
produced genome data, they usually create reports on certain
information. Most services provide an analysis of the genome
data in terms of ancestry information, health traits, paternity
tests, or cancer tests. Alternatively, some services offer
value-added interpretation, whereby they augment their
interpretation with additional services such as, for example,
carrying out legally binding paternity tests (as opposed to
cheaper nonlegally binding tests) or providing diet plans or
supplements based on the analysis of their consumers’ genome.
Capture Value
Capture value is the final category of business model
components. It pertains to three dimensions that describe how
DTC genetic testing service providers generate revenue. The
fee-type dimension is concerned with the providers’ pricing
model. Consumers may be charged on a per-use basis or on a
per-use basis paired with a subscription model (eg, to account
for additional services besides the actual test). Some tests are
offered to consumers free of charge. The fee-payer dimension
describes who pays for the offered tests. Tests can be paid for
entirely by consumers themselves as well as partly or completely
by the consumers’ health insurances. The reselling of genome
data dimension relates to whether a service provider generates
revenue from reselling collected genome data to third parties.
Possible customers for genome data include research institutes,
clinics, or pharmaceutical companies.
Archetypes of Direct-to-Consumer Genetic Testing
Services’ Business Models
The clusters in the 6-cluster solution comprise between 21 and
73 of the 277 DTC genomics services in our database. Thereby,
each cluster has a different focus regarding the dimensions and
characteristics of the DTC genetic testing service business model
taxonomy. As the taxonomy development method by Nickerson
et al [34] results in characteristics that are mutually exclusive
and collectively exhaustive, the data can be interpreted as
percentages. For example, 89% (42/47) of the companies in
cluster 1 operate worldwide whereas 11% (5/47) offer services
in their respective country only. Table MA6-1 in Multimedia
Appendix 6 provides an overview of the results of the cluster
analysis, whereby darker colors represent higher percentages
of services in the cluster belonging to a characteristic for the
corresponding dimension. We elaborate on each cluster below
by highlighting its most representative characteristics and
providing examples of typical DTC genomics services.
Cluster 1: Low-Cost Direct-to-Consumer Genomics for
Enthusiasts
The first cluster combines the low-cost genotyping tests offered
by companies like 23andMe (see Figure 2 for a screenshot of
their website) with the costlier sequencing tests provided by
companies like Veritas Genetics who strive to make sequencing
affordable for the enthusiast DTC market. These companies
operate worldwide as they provide their services over the
internet and less via multicontact channels. Most operators like
23andMe only charge the consumers a 1-time fee for their home
collection kit but claim the rights of the produced genome data
and utilize it to improve their own services and resell it for profit
to compensate for the relatively low prices of their tests. Other
services like Ancestry.com operate on a pay-per-use and
subscription fee model and therefore leave the ownership of the
data with the consumer. Finally, some services offer
health-related tests that are eligible for insurance coverage.
Although the offered services are value-added tests, services
either make it mandatory or give customers the option to
willingly participate in research with their data. Other prominent
examples of services in this cluster are FamilyTreeDNA,
MyHeritageDNA, or the Genographic Project.
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Figure 2. Screenshot of the 23andMe website from October 2019.
Cluster 2: High-Privacy Direct-to-Consumer Genomics
for Enthusiasts
Cluster 2 is in many aspects similar to cluster 1 but differentiates
itself in the crucial dimensions concerning the customers’ data
privacy. Most services in cluster 2, such as African Ancestry,
provide internet only or internet and telephone solutions for
genomic enthusiasts. African Ancestry provides a simple
genotyping test that answers the general question of whether a
customer has origins tracing to Africa and other information
regarding their African ancestry. The tests can only be taken
with a home collection kit and results are made available on the
Web. The generated genome data remain the property of the
consumer for all services in this cluster, and the genome data
are either erased or stored in an isolated storage accessible by
the consumer only. It is not sold for revenue. Furthermore, the
data are usually not used for research, but consumers may be
given the option to provide their data. The costs for these tests
are covered by a 1-time fee for the consumer or an additional
subscription. Other examples of services in this cluster include
EasyDNA, FitGenes, or The Makings of Me.
Cluster 3: Specific Information Tests
The third cluster holds DTC genetic testing services that provide
consumers with solutions to specific questions and aim to
provide a more elaborate service with value-added data
processing. One prominent example for this group is DNA
Diagnostics Center (see Figure 3 for a screenshot of their
website). Their choice of distribution channel over the internet
and via telephone allows for a worldwide service. DNA
Diagnostics Center offers a variety of genome tests on specific
information ranging from relationship to forensics on a 1-time
cost basis for the customer. Although all genome tests of this
cluster cover genotyping, the sample collection can either be
performed by the consumers themselves with a service-provided
home collection kit or by a professional (eg, for a legal paternity
test at a laboratory operated by DNA Diagnostics Center). The
genome data are primarily stored in isolation and sometimes
used to improve service quality (ie, the data are stored in a
database for later reference during the genotyping process),
whereas the consumers’ genome data are not used for inhouse
research or sold to a third party for revenue. Moreover, it is
often mandatory to store the sample (eg, for later reference of
legal relationship tests). This cluster holds several representative
service providers such as Alpha Biolabs, Dadchecksilver, or
Who’z the daddy.
Cluster 4: Simple Health Tests
Cluster 4 combines chronic health-related genomic services
such as Fulgent Diagnostics with the more casual health and
wellness focused services such as SkinDNA Canada. These
health-related services are either available through health
professionals only or multicontact services, which may also
include health professionals. This elaborate customer
relationship leads to many services only operating locally,
though some have a worldwide network. It comes as no surprise
that this cluster contains most services aimed at chronic health
issue and risk group consumers. Nevertheless, the cluster is still
mainly populated with specific information seekers and
enthusiast target groups. The 1-time fees are usually covered
by the consumers but may be covered by insurances as well.
The companies provide their own sampling kit and after
genotyping, the sample is destroyed if storing it is not necessary.
These services offer a lab collection option but come also with
a home collection kit. Although the data ownership remains
with the consumers and genome data are not sold for revenue
or utilized in research, the results are mostly basic reports, which
may require further interpretation by a local physician. Other
examples of services in this cluster include International
Bioscience or Pillcheck.
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Figure 3. Screenshot of the DNA Diagnostics Center website from October 2019.
Cluster 5: Basic Low-Value Direct-to-Consumer
Genomics
Cluster 5 differentiates itself from all other clusters in that it
contains for profit as well as nonprofit companies that either
charge a 1-time fee or offer services that are completely free.
As services like Genetic Genie rely mostly on third-party sample
collection, they can offer their services worldwide, exclusively
via the internet as the consumers choose the sampling provider
(eg, 23andMe) independently. The compatible sampling kits
are for home collection only and aimed at genotyping tests.
Consequently, the data ownership always lays with the
consumers for services in this cluster and if stored, the genomic
data are accessible for the costumers only. Furthermore, Genetic
Genie does not sell the data for revenue, and there is no research
consent option. As a result, the data processing is mostly done
automatically, and the resulting interpretation is only of a basic
nature. Nonetheless, enthusiasts may find a convenient way for
additional insight into their genome. Other members of this
cluster are Promethease, Roots for Real, or My Genetic Health.
Cluster 6: Comprehensive Tests and Low Data
Processing
Offering sequencing only or sequencing and genotyping tests,
the last cluster holds services focusing on the sample processing
mostly (ie, offering no or basic interpretation of the genome
data only). Dante labs (see Figure 4 for a screenshot of their
website), for example, offers a worldwide whole genome
sequencing home collection kit via their website with a basic
health analysis and Web access to the consumers’ entire
sequenced genome. Other services in this cluster offer other
forms of customer contact such as local labs or health
professionals. The sampling kit may be provided by the service
provider or additionally by a third party. Although this cluster
has no specific target group, services are always paid for by the
consumers with a 1-time fee. To compensate for the
comprehensive genome tests and generate profit, companies
often resell access to the produced genome data, make
participation in research mandatory, or claim the right to use
the data for company services. This is also mirrored in the data
ownership, which may lie with the customer as well as with the
company. Additional examples for services in this cluster are
Full Genomes Corporation, Helix, or Genes for Good.
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Figure 4. Screenshot of the Dante Labs website from October 2019.
Discussion
Principal Findings
Analysis of the taxonomy and derived archetypes unveils
interesting insights into the current state of the DTC genetic
testing market.
First, our results paint a much more heterogeneous landscape
of the DTC genetic testing market than most of the extant
literature in this area has conceived. This is not only highlighted
because of the presence of 6 diverse business model archetypes
that we identified but also supported by the fact that the
archetypes’ corresponding clusters are relatively evenly sized
with cluster 5 being the smallest (n=21) and cluster 3 being the
largest (n=73). Looking at the 5 business models described by
Vanhala and Reijonsaari [29], the business model archetypes
described here are rooted in a more diverse set of distinguishing
dimensions (ie, 15 dimensions as opposed to 5 dimensions).
This resulted in less (albeit still prevalent) emphasis on the
different value propositions and consumer target groups and
instead also included aspects such as major cost drivers (eg,
dimensions such as sampling site and sampling kit provider).
Furthermore, comparing the presented taxonomy with business
model taxonomies of other disruptive technologies [30,48,49],
we see that they share some similarities but also exhibit
distinctive differences. Accordingly, our taxonomy includes
several dimensions that are inherent to any business model,
especially those dimensions that are related to customer
segments, key partners, value propositions, or service pricing.
Our fee-type dimension, for example, is comparable with the
price structure dimension found in the carsharing business model
taxonomy of Remane et al [30], albeit with slightly different
characteristics. At the same time, however, the taxonomy
presented here also includes several dimensions whose
characteristics are more tailored toward the DTC genetic testing
market (eg, distribution channel, fee payer), as well as
dimensions that are entirely unique to the DTC genetic testing
context (eg, genome test type).
Second, much of the controversy surrounding DTC genetic
testing originates from concerns over the clinical value of such
tests [50], consumers’ capabilities of dealing with potentially
misleading test results [11], and the assumption that DTC
genetic testing services sell access to their consumers’ genomic
data to third parties [51]. To this end, cluster 1 seems to
represent a business model archetype that many skeptics of
DTC genetic testing services have in their minds when thinking
of DTC genetic testing. This is further supported by the fact
that the most prominent and probably most often criticized
players in the DTC genetic testing market such as 23andMe,
AncestryDNA, and FamilyTreeDNA can be found in this cluster.
The business model archetype represented by cluster 1 also
closely resembles the comprehensive genomic tests for
consumers and as genome data bank material business model
described by Vanhala and Reijonsaari [29]. Overall, however,
our analysis showed that the majority of DTC genetic testing
services do, for example, not resell access to their consumers’
genomic data to third parties for revenue (237 of 277). Even
more so, cluster 2 represents a business model archetype where
special emphasis is placed on consumers’ privacy. Several
explanations might exist for these surprising, yet interesting,
findings. Genomics, particularly DTC genetic testing, is still a
relatively young business [28]. Next to the dimensions in the
capture value category, the consumer research consent and data
ownership dimensions are especially deeply related to a DTC
genomics service provider’s profit as both dimensions exert a
strong influence on what service providers can and cannot do
with their primary resource, the produced genomic data. In this
regard, it is important to note that scale benefits are mostly on
the DTC genetic testing services’ side rather than the consumers’
side, as service providers can use already produced data to
improve their service quality. Some service providers might
also seek to incentivize interested individuals to use their service
to establish a large enough database of genomic data that they
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can then use to develop complementary revenue streams, which
do not directly involve selling access to genomic data to third
parties (eg, use collected data to develop new drugs).
Accordingly, some services might still be in a phase where
growth is considered more important than short-term profit by
the services’ stakeholders. Finally, some services might
anticipate further declining costs for genome data collection
and analysis because of technological advances, eventually
making them more profitable and changing the relative benefits
of different business models in the long run. An example for
such a service is Veritas Genetics, who seek to provide whole
genome sequencing services costing less than US $1000 to their
consumers.
The third interesting finding pertains to recent debates about
shifts in DTC genetic testing services’ strategies and the
emergence of what some call DTC genomics 2.0. Compared
with the currently prevailing DTC genomics paradigm, DTC
genomics 2.0 is characterized by a greater involvement of
regulatory bodies and health care professionals, a stronger
separation between health and nonhealth tests, and improved
support and counseling for consumers [6]. To this end, our
clusters show a clear separation between services mainly
targeting specific information seekers and people with chronic
diseases (clusters 3 and 4), and those primarily targeting
enthusiasts (clusters 1, 2, 5, and 6). Specifically, cluster 4
exhibits the largest number of services whose primary
distribution channel are health care professionals and services
whose tests are often paid for by consumers’ insurances. Cluster
4 represents a business model archetype that can serve as a
prime example for a shift toward DTC genomics 2.0. Although
such services arguably blur the lines between what is
traditionally considered DTC genetic testing (ie, genetic tests,
directly sold to consumers via the internet) and other forms of
genetic testing (eg, in clinical or research settings), we think
that the distinguishing factor is the primary recipient (ie, the
consumers themselves and not clinicians) rather than the form
of distribution or who actually pays for the tests. We also found
several services (28 of 277) that offer genome sequencing to
their consumers as opposed to only genotyping, potentially
providing higher accuracy and clinical value than pure
genotyping services. In consequence of these observations, our
research supports the notion of an ongoing shift in the DTC
genetic testing market to more mature DTC genomics 2.0.
Fourth, although most DTC genetic testing services were profit
oriented, we found it interesting that there were at least 14
nonprofit services in our sample. Although these services did
not form their own cluster in our 6-cluster solution, the majority
of these services (n=9) can be found in cluster 5. They almost
exclusively operate worldwide, only over the internet, and only
offer third-party home collection kits and genotyping services.
A notable exception to this is the DTC genetic testing service
of Genes for Good that operates only in the United States,
provides its own home collection kit and offers sequencing
services. It is a nonprofit organization run by the University of
Michigan, which seeks to engage people in genetic research.
Generally, nonprofit DTC genetic testing services heavily rely
on other for-profit DTC genetic testing services by, for example,
using the test kits of other services or directly requesting
consumers to import their data from other services. Specifically,
the last scenario, where consumers freely and openly share their
genome data with for-profit and nonprofit services, has received
attention from researchers interested in socioeconomic
perspectives of genome data sharing and crowdsourcing [1,24]
and could be seen as an indicator for a trend toward
platformization and a platform economy in genomics.
Limitations
Limitations of our study are as follows. First, the DTC genetic
testing market is a volatile market with new services regularly
appearing, mergers and acquisitions constantly happening, and
extant services disappearing or changing their business
strategies. Our taxonomy and archetypes, however, represent a
snapshot of the current landscape of DTC genetic testing service
business models. It is likely that in the meantime, new services
would have emerged, while some services in our sample would
have changed their business models or completely disappeared
from the market. Nevertheless, we are confident that the
developed taxonomy and derived archetypes build a strong
foundation for further research in this area because of the rich
and meaningful sample of DTC genetic testing services used
and rigorous development of both. Moreover, owing to the
extendibility ending condition being met, the presented
taxonomy can easily be extended or altered in the case of the
emergence of new services or additional insights. Second, our
examination of services was mainly based on information
retrieved from nonscientific sources and services’ internet
presences. Some information provided was ambiguous or not
given at all. It is possible that our coding of some of the services
are not entirely appropriate. We sought to address these
information deficits by having services examined by 2
researchers independently, consulting additional internet sources,
and, where no information was found, making informed guesses
by comparing specific services with other similar services.
Third, although Ward’s method indicated the validity of several
cluster solutions, analysis of common metrics provided
inconclusive results on which cluster solution to choose for the
k-means algorithm (ie, the dendrogram suggested 4, 5, and 6
cluster solutions, whereas the scree plot suggested 4, 5, 7, and
9 cluster solutions). After thorough examination of these cluster
solutions based on a k-means clustering, we deemed the 6-cluster
solution to be the most promising one for this research.
Nevertheless, the 7-cluster solution might have provided
additional insights into the DTC genomics market, which are
not captured by the current cluster solution.
Implications and Future Research
Our study yields several implications for research and practice.
For research, we provide a systematic classification of DTC
genetic testing service business models and expose their
essential characteristics. The developed taxonomy adds to our
knowledge of business models in genomics, and in conjunction
with the proposed archetypes, it contributes to a more
comprehensive understanding of the DTC genetic testing
industry. Compared with other taxonomies about technologies
that are similarly disruptive as DTC genetic testing [35], the
taxonomy presented here focuses on a rather narrow aspect of
the DTC genetic testing service phenomenon. Although the
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objective of this research was specifically to analyze an area of
DTC genetic testing that has received little attention from
researchers thus far (ie, the business models in this very
industry), we also think that the presented taxonomy can serve
as a starting point to analyze the DTC genetic testing
phenomenon as a whole by, for example, broadening the
taxonomy’s scope and further developing it into a general
taxonomy of DTC genetic testing services. However, we also
note that despite the seminal work of Hwang and Christensen
[8], the literature on the classification of business models in
health care remains scarce. The presented taxonomy and
archetypes can serve as an outset for new avenues in future
research on DTC genetic testing. Starting from the previously
outlined limitations of this study, researchers could seek to
replicate the results of our research, especially considering the
likely emergence of new DTC genetic services. Furthermore,
as the taxonomy and archetypes only capture a snapshot of
current DTC genetic testing service business models, future
research should also attempt to analyze how those services’
business models change over time. To this end, the literature
on business model innovation [52,53] could provide a promising
foundation to analyze the evolution of business models in DTC
genetic testing. Although the clusters presented in this work
were developed independent of any temporal dimension, future
research may also investigate whether these clusters relate to
different evolutionary stages of DTC genetic testing business
models. From a socioeconomic and genetic privacy research
perspective, our research provides a starting point to better
understand the economic value of genomic data. We thereby
support and strengthen the notion of information privacy as a
commodity that can be traded in the context of genomics [54].
Specifically, dimensions in the categories such as strategic
choices, create value, and capture value might prove useful to
better understand the relationships between business models,
genetic privacy, and crowdsourcing in genomics.
In terms of practice, our research has important implications
for policy makers, professionals in the health care industry,
DTC genetic testing services themselves, and consumers of
such services. For policy makers, our research highlights a
reality of diverse business models within the DTC genetic testing
market. Considering DTC genetic testing services’ need to
collaborate closely with regulatory bodies, the developed
taxonomy and archetypes can assist policy makers in designing
policies that adapt to the diverse business landscape as to better
protect consumers’ well-being and privacy while respecting
their right to informational self-determination. Similarly, the
archetypes of DTC genetic testing service business models help
raise awareness for the existence of different kinds of services
with diverse benefits and risks for consumers and the health
care system. Overall, our work contributes to a more nuanced
understanding of DTC genetic testing in the health care sector,
which has become progressively important given that evidence
from studies among U.S. populations (one of the largest DTC
genetic testing markets) suggests patients increasingly talk to
their primary care physicians about DTC genetic testing [55,56],
and expect them to be able to answer questions about DTC
genetic test results [57]. For DTC genetic testing services,
especially young services, our taxonomy serves as a valuable
tool to analyze and possibly further develop their own business
models as well as to analyze competitors’ business models. The
presented archetypes provide decision makers of DTC genetic
testing services with blueprints of potential business models.
Such blueprints can be used as initial guidance for transitioning
from 1 business model to another or to identify market niches.
From a consumer’s point of view, it was a pleasant surprise that
most DTC genetic testing service providers do not resell access
to their consumers’ genomic data to third parties. However, at
the same time, our analysis reveals that many of the examined
DTC genetic testing services retain the right to use collected
genomic data for service improvements, something which
consumers should be aware of. Overall and in line with research
seeking to understand and improve consumers’ understanding
of DTC genetic testing [13,14], the taxonomy and archetypes
presented in this study can serve consumers as tools for
assessing DTC genetic testing services and finding services that
best fit their needs.
Conclusions
DTC genetic testing is a relatively young and dynamic business
area, which pushes genomics research forward and promises
faster, as well as more affordable genomics services. Despite
the rapid growth of the business sector, many concerns remain
unanswered, and there is little knowledge about the impact of
business models on DTC genetic testing services within research
literature. In this study, we provide the first overview of DTC
genetic testing service business models, resulting in a rigorously
developed taxonomy and 6 service archetypes. This provides
novel insights into the value and use of genomic data and can
serve as a foundation for advanced research on relationships
among DTC genetic testing services, their consumers,
practitioners within the health care sector, and policy makers.
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